Petrelintide
ZUPREME
Roche · Phase 2 · Completed · Enrollment 493
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Petrelintide Dose 1 | n/r | n/r | n/r | n/r |
| Petrelintide Dose 2 | n/r | n/r | n/r | n/r |
| Petrelintide Dose 3 | n/r | n/r | n/r | n/r |
| Petrelintide Dose 4 | n/r | n/r | n/r | n/r |
| Petrelintide Dose 5 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Petrelintide Dose 1: endpoint not reported
- Petrelintide Dose 2: endpoint not reported
- Petrelintide Dose 3: endpoint not reported
- Petrelintide Dose 4: endpoint not reported
- Petrelintide Dose 5: endpoint not reported
- Placebo: endpoint not reported